Dynavax Technologies sees one or more of its collaboration partners commence a Phase 1 clinical trial of a potential COVID-19 vaccine as soon as July 2020.
- Co. to provide an update on its early-stage collaborations regarding the potential development of a vaccine for COVID-19 on May 19
- Co. shares up about 20% post-market
To view the source of this information click
To contact the reporter on this story:
To contact the editor responsible for this story:
© 2020 Bloomberg L.P. All rights reserved. Used with permission.